Vascarta Inc.
Vascarta is a clinical-stage pharmaceutical company focused on advancing innovative treatments for pain and inflammation. Our team of scientists has developed a patented topical-transdermal delivery technology that enables the effective use of curcumin, a compound with well-established anti-inflammatory properties. By delivering curcumin transdermally, we overcome the bioavailability limitations commonly associated with oral administration.
Our lead candidate, Vasceptor® (VAS-101), has demonstrated significant efficacy in multiple preclinical animal studies. These promising results have paved the way for clinical development programs targeting Sickle Cell Disease and Osteoarthritis.
Phase 1 proof-of-concept clinical trials in human subjects commenced in Q1 2025, with completion anticipated by Q4 2025.
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}